论文部分内容阅读
临床试验表明降低低密度脂蛋白胆固醇(LDL-C)能减少高胆固醇血症的中年人冠状动脉疾患(CAD)的发病率。但是,尚未证实增加高密度脂蛋白胆固醇(HDL-C)和降低甘油三酯对减少CAD危险性有类似作用。苯扎贝特心梗预防试验的主要目的是观察CAD患者长期应用苯扎贝特后是否能降低由于冠脉粥样硬化所造成的致命和非致命性冠脉事件的发生率.其次是观察对总死亡
Clinical trials have shown that lowering LDL-C can reduce the incidence of coronary heart disease (CAD) in middle-aged people with hypercholesterolemia. However, it has not been demonstrated that increasing HDL-C and lowering triglycerides have similar effects on reducing CAD risk. The main purpose of bezafibrate myocardial infarction prevention trials is to observe whether long-term use of bezafibrate in CAD patients can reduce the incidence of fatal and non-fatal coronary events caused by coronary atherosclerosis, followed by observation of Total death